Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

详细信息    查看全文

• 作者：Yu-Ching Weng¹ ; Chien-Shan Chiu¹ ; Tseng-Hsi Lin² ; ³ ; ⁴ ; Jui-Lung Shen¹ ; Chii-Shuenn Yang⁵ ; Joe-Bin Chen⁶ ; ^{jbchen@vghtc.gov.tw" class="auth_mail" title="E-mail the corresponding author}
• 关键词：BRAF inhibitor ; drug reaction ; erythema nodosum ; melanoma ; panniculitis ; vemurafenib
• 刊名：Dermatologica Sinica
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：34
• 期：2
• 页码：88-91
• 全文大小：1327 K

文摘

The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40–60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic melanoma. We report a case of metastatic amelanotic melanoma with unknown primary cancer as the initial presentation. The patient presented with neutrophilic septal panniculitis 1 week after vemurafenib treatment, which is a rare cutaneous toxicity of BRAF inhibitor. We also review the current literature on management of BRAF inhibitor-related adverse skin effects.